| Systematic (IUPAC) name | |
|---|---|
| 2-(4-bromo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine | |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | ? |
| Identifiers | |
| CAS number | 1026511-90-9 |
| ATC code | ? |
| PubChem | CID 9977044 |
| ChemSpider | 8152636 |
| Chemical data | |
| Formula | C18H22BrNO3 |
| Mol. mass | 380.275 g/mol |
| SMILES | eMolecules & PubChem |
|
|
| |
|
25B-NBOMe (NBOMe-2C-B, BOM 2-CB, Cimbi-36) is a derivative of the phenethylamine hallucinogen 2C-B, discovered in 2004 by Ralf Heim at the Free University of Berlin. It acts as a potent partial agonist for the 5HT2A receptor.[1][2][3][4] Anecdotal reports from human users suggest 25B-NBOMe to be an active hallucinogen at a dose of as little as 400-650mcg insufflated, making it a similar potency to other phenethylamine derived hallucinogens such as bromo-dragonfly. Duration of effects lasts about 10h.
| This psychedelics, dissociatives and deliriants-related article is a stub. You can help Wikipedia by expanding it. |
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)